RxDoctor Payments Data

Diane Pfeifer, MD

Internal Medicine · Kokomo, INNPI 1730183450

Payments from drug & device makers

$468in general payments, 2019–2025

Across 28 payments — averaging $16.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$161
  • Pfizer$106
  • Biohaven Pharmaceuticals, Inc.$76
  • Phathom Pharmaceuticals, Inc.$33
  • Novo Nordisk$32
  • Lilly USA, LLC$27
  • plus $33 from 2 others

What the payments were for

  • Food & beverage$45697%
  • Education$123%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$468 in reported general payments places this provider in the 65th percentile of 1,747 internal medicine providers in Indiana.

See all internal medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$136,480
Medicare patients
494
Services billed
1,290

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban148$183,699
JardianceEmpagliflozin152$170,225
OzempicSemaglutide54$116,919
TrulicityDulaglutide50$98,584
MounjaroTirzepatide54$92,763
Teriparatide24$71,284
JanuviaSitagliptin Phosphate57$67,539
RybelsusSemaglutide35$58,592
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$37,547
Combivent RespimatIpratropium/Albuterol Sulfate15$30,239
FarxigaDapagliflozin Propanediol28$30,165
TradjentaLinagliptin28$23,066
JanumetSitagliptin Phos/Metformin Hcl15$21,655
LinzessLinaclotide20$18,074
Tresiba Flextouch U-100Insulin Degludec19$17,972

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$106$197,277174 claims
Lilly USA, LLCTrulicity, Mounjaro$27$191,346104 claims
Novo NordiskOzempic, Rybelsus$32$175,51189 claims
AbbVieLinzess, Qulipta, Synthroid$161$33,16389 claims
AstraZenecaFarxiga$17$30,16528 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,747 internal medicine providers in Indiana.

Other internal medicine in Kokomo

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →